Pharmaceutical Technology

MAY 8, 2023

In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Innovation in Pharmaceuticals: Anti-influenza antibody compositions. However, not all innovations are equal and nor do they follow a constant upward trend.

Antibody 246

Antibody Vaccination Vaccine Dermatology 246

BioSpace

APRIL 3, 2024

Amid a flurry of deals in the antibody-drug conjugate space, Merck KGaA is getting in on the action with a partnership with Caris Life Sciences to accelerate the discovery and development of first-in-class ADCs for oncology.

Life Science 68

Life Science Development Antibody Drugs 68

XTalks

MAY 9, 2024

Genmab, a trailblazer in the field of antibody therapeutics, celebrates this milestone by reflecting on its impressive journey from a small-scale startup to a global leader in cancer treatment and beyond. Since then, innovative science has been at Genmab’s core, as we harness the power of human antibodies to improve the lives of patients.

Antibody 52

Antibody Clinical Trials Clinical Trials Medicine 52

Drug Discovery World

APRIL 27, 2023

Biotechnology company Tiziana Life Sciences is initiating a programme to develop intranasal foralumab for the treatment or prevention of type 1 diabetes. We believed that having a fully human CD3 antibody may offer benefits to patients across many different chronic disease indications.”

Antibody 52

Antibody Development Life Science FDA Approval 52

Pharmaceutical Technology

JULY 20, 2022

TSB Therapeutics, a joint venture (JV) majority-owned by Brii Biosciences (Brii Bio), has entered a collaboration with China Resources Pharmaceutical Commercial Group (CR Pharma) for the commercialisation of an antibody therapy, amubarvimab/romlusevimab combination, for Covid-19 in China. .

Antibody 147

Antibody Life Science Production Development 147

XTalks

FEBRUARY 23, 2022

The team also talked about Eli Lilly’s new COVID-19 monoclonal antibody bebtelovimab that received emergency use authorization (EUA) from the US Food and Drug Administration (FDA) indicated for patients with mild to moderate COVID-19 who are at risk of progressing to severe disease.

Life Science 52

Life Science Antibody Vaccination Vaccine 52

Pharmaceutical Technology

JUNE 9, 2023

Co-led by Venrock Healthcare Capital Partners (Venrock) and Enavate Sciences, the financing round has seen participation from new investors Wellington Management and Bain Capital Life Sciences. It is also preparing for a swift transition to Phase III development.

Clinical Development 147

Clinical Development Development Life Science Clinical Trials 147

Drug Discovery World

JULY 3, 2023

It’s a challenging time to launch a new company in the life sciences sector. The company is developing immunotherapies against human endogenous retroviruses (HERVs) to treat various cancers from within, a previously undruggable target. Irvine expands on this further: “Starting a company in life sciences is always challenging.

Life Science 52

Life Science Pharma Companies Drugs Marketing 52

Drug Discovery World

FEBRUARY 28, 2024

Lu Rahman selects some of the year’s interesting and noteworthy advances in cancer research drug discovery and development. As always, a year within cancer drug discovery and development brings with it significant breakthroughs, and 2023 has been no exception. Figures from the Amercian Cancer Society 1 state that “a little over 1.9

Development 64

Development Research Drugs Antibody 64

XTalks

OCTOBER 4, 2023

Immunogenicity data from the study showed sustained HPV-antibody responses ten years after administration of the third dose in both boys and girls. Joura about the new long-term HPV vaccine data and the importance of increasing vaccine coverage, particularly in the developing world, in the prevention of HPV-related cancers.

Life Science 52

Life Science Vaccination Vaccine Antibody 52

BioTech 365

OCTOBER 12, 2021

NanoString Launches nCounter Antibody Drug Conjugate Panel to Accelerate the Development of Oncology Treatments NanoString Launches nCounter Antibody Drug Conjugate Panel to Accelerate the Development of Oncology Treatments SEATTLE–(BUSINESS WIRE)–NanoString Technologies, Inc.

Antibody 52

Antibody Development Life Science Drugs 52

pharmaphorum

MAY 20, 2021

Switzerland’s Numab has raised 100 million Swiss francs – around $110 million – in Series C financing to develop bispecific antibodies for cancer and inflammation, with Novo Noldings and HBM Partners co-leading the investor syndicate. The post Numab raises $110m to develop cancer bispecific antibodies appeared first on.

Antibody 52

Antibody Development Clinical Development Life Science 52

Drug Discovery World

FEBRUARY 19, 2024

Dr Julie Warner is Vice President of Regulatory Affairs at drug development consultancy, Boyds. In this article, she provides her expert insights into the key trends and developments expected to shape the global drug development industry this year. antibody-drug conjugate [ADC] pipelines in some oncology settings).

Development 59

Development Gene Therapy Drugs Antibody 59

XTalks

DECEMBER 17, 2021

Xtalks is taking a look at some of the major stories and innovations of the year in the life sciences, many of which were driven by new, emerging and improved technologies. The year 2021 was all about continuing innovations in the life sciences. COVID-19: The Pandemic and the Vaccines.

Life Science 98

Life Science Vaccination Vaccine Trials 98

XTalks

AUGUST 10, 2022

In this episode, Ayesha discussed a new COVID-19 test technology that Innova Medical Group, world leader in at-home COVID-19 tests, has reached a licensing deal for with the University of Birmingham where the technology was developed. Subscribe to the Xtalks Life Science Podcast to never miss a new episode.

Life Science 52

Life Science FDA Approval Drugs Licensing 52

XTalks

JANUARY 5, 2021

There will also be more focus on digitization of research and development and manufacturing spaces to increase efficiencies and interconnectivity in the pharma, biotech and medical device industries. These include monoclonal antibody drugs, which are attractive therapeutic agents owing to their targeted specificity.

Life Science 98

Life Science Clinical Trials Clinical Trials Trials 98

The Pharma Data

MARCH 15, 2022

Investment will accelerate the overall Sarclisa ® development program Sanofi will continue to fully manage the clinical program and retain full rights and control of Sarclisa ® (isatuximab). to advance the development of a subcutaneous delivery for Sarclisa ® with the goal of offering a unique patient-centric treatment experience.

Life Science 52

Life Science Antibody Clinical Trials Clinical Trials 52

Drug Discovery World

JANUARY 10, 2023

For over 50 years, Bethyl Laboratories (now a Fortis Life Sciences brand) has been dedicated to improving lives by supporting scientific discovery through qualified antibody products and custom services. Antibody validation. Antibody validation. A proposal for validation of antibodies.

Antibody 52

Antibody Protein Reagent Scientist 52

Drug Discovery World

JULY 18, 2022

Life sciences company Carterra has joined data cloud company TetraScience’s network of partners to help generate insights into the potential of antibodies as drug candidates. . In turn, AI and data science will uncover insights that will accelerate discovery and development of therapeutics that extend and enhance human life.

Antibody 52

Antibody Life Science Drugs Development 52

The Pharma Data

JUNE 1, 2022

AstraZeneca’s Chief Executive Officer, Pascal Soriot, today received a British knighthood for services to UK life sciences and leadership in the global response to the COVID pandemic in the Queen’s Birthday Honours 2022. Alongside leading AstraZeneca, Pascal is also driving change across the healthcare sector and beyond.

Life Science 52

Life Science Medicine Vaccination Vaccine 52

The Pharma Data

NOVEMBER 30, 2020

Shailubhai will provide updates on the Company’s proposed move from AIM to the Standard Segment of the Main Market of the London Stock Exchange, ongoing clinical trials, as well as other recent developments in Tiziana Life Sciences. About Tiziana Life Sciences. NEW YORK and LONDON, Dec.

Life Science 40

Life Science Antibody Clinical Trials Clinical Trials 40

pharmaphorum

JULY 19, 2021

‘Shaping the UK into an epicentre for complex medicines’ is a report by the Medicines Discovery Catapult (MDC) in partnership with the CPI showcasing the extensive potential for the UK in developing complex medicines. Two-thirds wanted to see more collaborative partnerships in the development of complex medicines.

Life Science 52

Life Science Medicine RNA Vaccination 52

BioSpace

OCTOBER 14, 2021

Read about TFF Pharmaceuticals and Augmenta Bioworks' dry powder COVID-19 antibody formula, the world's first gene editing clinical trial for PKU, Bayer's COVID-19 vaccine and other key developments in life sciences research.

Gene Editing 90

Gene Editing Life Science Clinical Trials Clinical Trials 90

Drug Discovery World

APRIL 3, 2023

I quickly recognised the commercial value of aptamers as being able to address the gap in the market where antibodies fail to perform, and together we established the business to begin aptamer development. DS: How are aptamers currently used in the development of precision treatments?

Antibody 52

Antibody Gene Therapy Gene In-Vitro 52

XTalks

SEPTEMBER 30, 2020

The research shows that the activity of the immune messenger type 1 interferon (IFN) protein is diminished, either by genetic mutations or an autoimmune attack by neutralizing antibodies against it, in a subset of COVID-19 patients. These rogue antibodies blocked interferon action and were not present in patients with mild COVID-19 cases.

Antibody 135

Antibody Genetics Research In-Vitro 135

XTalks

NOVEMBER 4, 2020

It has long been known that mothers greatly influence the development of the growing fetus by not only providing nutrients through the placenta, but also a growing list of biological elements including beneficial antibodies, gut bacteria and now, allergies. They reported their findings last week in the journal Science.

Allergies 98

Allergies Antibody In-Vitro Development 98

The Pharma Data

JANUARY 3, 2021

Dr. Kunwar Shailubhai, CEO and CSO of Tiziana Life Sciences, commented: “While we expect to get the topline data in January 2021, we are delighted with the positive feedback received from the treated patients. About Tiziana Life Sciences. . NEW YORK and LONDON, Jan. +44 (0)20 7495 2379. .

Life Science 40

Life Science Clinical Trials Clinical Trials Antibody 40

XTalks

JULY 28, 2021

Ayesha and the team talked about the controversial approval of the drug, with lingering questions about its clinical benefit despite having the ability to reduce amyloid plaques as an anti-amyloid monoclonal antibody.

Life Science 52

Life Science FDA Approval Drugs Antibody 52

pharmaphorum

JANUARY 13, 2021

IO Biotech, an oncology specialist formed and backed by Denmark’s Novo Holdings, has raised €127 million ($155 million) to further develop its cancer vaccine technology that has boosted efficacy of PD-1 immunotherapy in early trials. The post IO Biotech raises $155m to develop breakthrough cancer vaccine appeared first on.

Vaccination 90

Vaccination Vaccine Development In-Vivo 90

The Pharma Data

SEPTEMBER 4, 2020

The technique has been used to generate a high-affinity antibody against Arginase 2, an enzyme implicated in major human diseases. Therefore, the enzyme is a target for inhibitory therapeutic antibodies that could help restore immune function against cancer cells, the researchers note.

Antibody 52

Antibody Research Life Science Production 52

XTalks

JUNE 18, 2021

This is why Regeneron’s announcement of positive clinical trial results that show its antibody cocktail treatment can cut deaths among hospitalized patients is welcome news. It is the first trial to demonstrate that any antibody treatment could improve survival in patients hospitalized with COVID-19. Regeneron Pharmaceuticals Inc.’s

Antibody 75

Antibody Immune Response Trials Clinical Trials 75

XTalks

JULY 25, 2022

Later lines of treatment can include monoclonal antibodies, tyrosine kinase inhibitors and antibody-drug conjugates (ADCs). ADCs consist of an antibody attached to a cytotoxin that is delivered to targeted cells. XTALKS WEBINAR: Discussing the Concerns within Clinical Research in Oncology and In-Home Healthcare.

Antibody 59

Antibody Drugs Clinical Trials Clinical Trials 59

The Pharma Data

NOVEMBER 10, 2020

First Ever Study with take-home capsules of Foralumab , a Fully Human Anti-CD3 Monoclonal Antibody. Weiner, chairman of the scientific advisory board of Tiziana Life Sciences, commented: “We understand that this will be the first-ever study with ‘take-home’ capsules of any mAb for immunotherapies for human diseases.

Life Science 40

Life Science Clinical Trials Clinical Trials Trials 40

The Pharma Data

JANUARY 26, 2021

27, 2021 (GLOBE NEWSWIRE) — Tiziana Life Sciences plc (Nasdaq: TLSA / LSE: TILS), a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases, today announces that it has filed a “universal” shelf registration statement on Form F-3 (File No. About Tiziana Life Sciences.

Life Science 40

Life Science Sales Antibody Marketing 40

pharmaphorum

OCTOBER 12, 2022

Now, he leads Whitelab Genomics as its artificial intelligence (AI) platform powers the development of genomic therapies – an emerging field in which genetic sequences are injected into cells to target and repair damaged genes. We have been very impressed by their vision and the relevance of their platform.”.

Genome 103

Genome Genomics Medicine Development 103

Drug Discovery World

JULY 11, 2023

Tim Lowery , President, JSR Life Sciences, asks whether artificial intelligence can do for life sciences what it has done in other sectors and whether these tools can keep up with the complexities of human biology. So, where do we go from here to realise their potential in life sciences?

Big Data 40

Big Data Development Life Science Drugs 40

Drug Discovery World

OCTOBER 20, 2022

DDW Multimedia Editor Megan Thomas takes a broad look at the drug discovery and development landscape in Japan and highlights how it is bolstered by government policies, investment, collaboration, start-up ecosystems and academic research. . Developing and securing human resources with digital skills.

Development 52

Development Drugs Life Science Marketing 52